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Abstract
Background: Assessment of DNA promoter methylation markers in cervical scrapings for the detection of cervical
intraepithelial neoplasia (CIN) and cervical cancer is feasible, but finding methylation markers with both high sensitivity
as well as high specificity remains a challenge. In this study, we aimed to identify new methylation markers
for the detection of high-grade CIN (CIN2/3 or worse, CIN2+) by using innovative genome-wide methylation
analysis (MethylCap-seq). We focused on diagnostic performance of methylation markers with high sensitivity
and high specificity considering any methylation level as positive.
Results: MethylCap-seq of normal cervices and CIN2/3 revealed 176 differentially methylated regions (DMRs)
comprising 164 genes. After verification and validation of the 15 best discriminating genes with methylation-
specific PCR (MSP), 9 genes showed significant differential methylation in an independent cohort of normal
cervices versus CIN2/3 lesions (p < 0.05). For further diagnostic evaluation, these 9 markers were tested with
quantitative MSP (QMSP) in cervical scrapings from 2 cohorts: (1) cervical carcinoma versus healthy controls
and (2) patients referred from population-based screening with an abnormal Pap smear in whom also HPV
status was determined. Methylation levels of 8/9 genes were significantly higher in carcinoma compared to
normal scrapings. For all 8 genes, methylation levels increased with the severity of the underlying histological
lesion in scrapings from patients referred with an abnormal Pap smear. In addition, the diagnostic
performance was investigated, using these 8 new genes and 4 genes (previously identified by our group:
C13ORF18, JAM3, EPB41L3, and TERT). In a triage setting (after a positive Pap smear), sensitivity for CIN2+ of
the best combination of genes (C13ORF18/JAM3/ANKRD18CP) (74 %) was comparable to hrHPV testing (79 %),
while specificity was significantly higher (76 % versus 42 %, p ≤ 0.05). In addition, in hrHPV-positive scrapings,
sensitivity and specificity for CIN2+ of this best-performing combination was comparable to the population
referred with abnormal Pap smear.
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Conclusions: We identified new CIN2/3-specific methylation markers using genome-wide DNA methylation
analysis. The diagnostic performance of our new methylation panel shows higher specificity, which should
result in prevention of unnecessary colposcopies for women referred with abnormal cytology. In addition,
these newly found markers might be applied as a triage test in hrHPV-positive women from population-based
screening. The next step before implementation in primary screening programs will be validation in
population-based cohorts.
Keywords: Cervical cancer screening, Cervical precancerous lesions, Human papillomavirus (HPV), Cervical
scraping, MethylCap-seq, DNA methylation, Quantitative methylation-specific PCR (QMSP)
Background
Cervical cancer is characterized by a well-defined pre-
malignant phase, cervical intraepithelial neoplasia (CIN).
Identification of these high-grade CIN (HSIL) lesions by
population-based screening programs and their subse-
quent treatment has led to a significant reduction of the
incidence and mortality of cervical cancer [1, 2].
Cytology-based testing of cervical smears is the most
widely used cervical cancer screening method but is not
ideal, as the sensitivity for detection of CIN2 and higher
(CIN2+) is only ~55 % [3–5, 51]. Cervical carcinogenesis
is highly associated with high-risk human papillomavirus
(hrHPV) [6]. Large randomized controlled trials have
shown that the sensitivity of hrHPV testing is significantly
higher than cytology testing [4, 7–10]. Based on these
data, starting in 2016, the Netherlands is one of the first
countries to implement hrHPV testing as primary cer-
vical cancer population-based screening. However, the
specificity of hrHPV testing, especially in a young
screening population, is relatively low [3, 11–13], which
may lead to unnecessary referrals to the gynecologist,
anxiety in the false-positive women, and higher costs for
the health-care system. Finally, in the near future, the
prevalence of CIN and cervical cancer will probably de-
crease in countries that have introduced primary pre-
vention with hrHPV vaccination. With this decrease in
prevalence, the positive predictive value of the current
screening tests will by definition decrease [14]. There-
fore, other objective biomarkers with both high sensitiv-
ity as well as high specificity are needed as new
screening tools for cervical cancer.
Different DNA methylation patterns in normal versus
(pre)malignant lesions represent excellent targets for
diagnostic approaches based on methylation-specific
PCR (MSP). Promoter hypermethylation of tumor sup-
pressor genes is an early event in cervical carcinogenesis
and consequently hypermethylation analysis can be espe-
cially relevant for the early detection of cervical neopla-
sia [15–17]. Assessment of methylation markers in
cervical scrapings for the detection of CIN and cervical
cancer is feasible [17–23], but obtaining methylation
markers with both high sensitivity as well as high
specificity remains a challenge. Through the years, grad-
ually more sophisticated approaches have been devel-
oped to identify new methylation markers on a genome-
wide scale [24]. Amidst comparable studies from other
groups, we have previously reported our experience with
pharmacological unmasking of the promoter region
combined with re-expression as analyzed by microarrays,
high-throughput quantitative methylation-specific PCR
(QMSP) on an OpenArray platform, and methyl-DNA
immunoprecipitation followed by microarray analysis
(MeDIP), resulting in the discovery and validation of the
genes C13ORF18, JAM3, EPB41L3, and TERT [21, 22, 25].
The diagnostic performance of these genes showed sensi-
tivities for detecting CIN2+ in a hrHPV-positive popula-
tion between 43 and 71 % and specificities between 89
and 100 % [21]. However, most strategies (including ours)
for discovering new methylation markers so far were
based on the difference between cancer and normal tissue
resulting in markers with high sensitivity for carcinoma,
but with too low sensitivity for detecting CIN2/3 lesions
[21, 22, 26, 27]. New and more specific innovative
genome-wide methylation analysis of DNA from CIN2/3
lesions versus normal cervical tissue should result in
(new) CIN2/3-sensitive and -specific methylation markers.
MethylCap-seq uses methyl-binding domain (MBD) pro-
teins to specifically enrich for methylated DNA, followed
by sequencing [28, 29]. The higher affinity of the MBD
complex for double-stranded CpG-methylated DNA
results in a higher enrichment for methylated DNA se-
quences as compared to MeDIP analysis. Using next-
generation sequencing, a unique methylome of each
sample will be generated (MethylCap-seq). After iden-
tification of novel methylation markers for (pre)malig-
nant cervical neoplasia through this approach, validation
and diagnostic evaluation of these newly found markers
can be performed.
The aim of the present study was to identify new
methylation markers that can differentiate between nor-
mal cervices and CIN2/3 lesions using MethylCap-seq
with high specificity and high sensitivity. To validate the
diagnostic performance of the newly found methylation
markers considering any methylation level as positive,
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cervical scrapings will be tested as triage test after either
primary cytology or primary hrHPV analysis using
QMSP. Because for most of the reported markers in lit-
erature a cut-off value was set above a certain methyla-
tion level in order to obtain high specificity, we will
preferentially select differentially methylated markers
without setting a cut-off allowing a test that should be
more objective and easy to interpret.
Results
Identification of differential methylated genes by
MethylCap-sequencing
To identify new CIN2 or higher (CIN2+) specific methyla-
tion markers, we applied the strategy as shown in Fig. 1.
In short, genome-wide MethylCap-seq was used to
compare the DNA methylation profiles of CIN2/3 dys-
plastic cervical cells with normal cervical cells to identify
CIN2/3-specific differential methylated regions (DMRs).
After applying our selection criteria (see “Methods” sec-
tion for detailed description), 176 DMRs comprising 164
genes remained. The list of DMRs is shown in Additional
file 1: Table S1, ranked on the sum of unmethylated nor-
mal samples and methylated CIN2/3 samples. The range
of reads obtained for all these 176 DMRs of all samples
considered methylation positive was from 3–17 reads with
a median of 4 reads (data not shown).
Verification and validation of the top 15 differentially
methylated genes
To verify the MethylCap-seq data, the top 15, out of the
163 identified genes, were selected. Methylation-specific
PCR (MSP) primers were designed and could be opti-
mized for 14 out of the 15 genes. Verification of the se-
lected 14 genes showed for 11 genes a significant
correlation between the MSP band intensity and the
amount of reads from the MethylCap-seq data. One
gene (PCDH17) showed high methylation levels in leu-
kocytes and was excluded for further validation in order
to prevent false-positive methylation signals in samples
of healthy women. The remaining 10 genes passed verifi-
cation and continued to the subsequent validation step.
Table 1 shows an overview of which genes continued
through the different stages of validation.
The second validation step was performed by MSP on
DNA isolated from FFPE tissue of an independent, ran-
domly selected new patient cohort that consisted of 13
cervical cancers, 19 HSIL lesions (8 CIN2, 8 CIN3, and
3 adCIS) and 17 normal cervices. Out of the 10 genes
analyzed, 9 were not methylated in almost all normal
samples, significant differential methylation between
normal versus HSIL lesions and again little to no methy-
lation in the leukocytes (p < 0.05) (Table 2). These 9
genes (ZSCAN1, ST6GALNAC5, ANKRD18CP, PAX2,
CDH6, GFRA1, GATA4, KCNIP4, and LHX8) were
MethylCap-seq:
18 CIN2/3 lesions versus 20 normal cervices 
MSP frozen tissue:
Correlating MSP bands with MethylCap-seqdata 
MSP new patient cohort: 
13 carcinoma. 19 CIN2/3. 17 normal cervices 
QMSP scrapings:
100 carcinoma versus 89 normal cervices
QMSP scrapings with abnormal cytology: 
No CIN (n=27). CIN1 (n=38). CIN2 (n=49).
CIN3 (n=57). miCa(n=44) 
Identification 
Verification
Validation
1st Diagnostic evaluation
2nd Diagnostic evaluation
Fig. 1 Flow scheme for the identification of new CIN2+ methylation markers
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selected for further diagnostic evaluation in cervical
scrapings (Table 2).
Diagnostic evaluation by QMSP for normal versus cancer
scrapings
To evaluate the diagnostic value of the new methylation
markers (Table 2), cervical scrapings from two cohorts
of patients were used: (1) normal versus carcinoma
scrapings and (2) scrapings from patients referred from
population-based screening with an abnormal Pap
smear (≥pap2).
In cohort 1, cervical scrapings of 100 randomly se-
lected cervical carcinoma patients and of 89 patients
with histologically confirmed normal cervices were used.
QMSP analysis showed that the relative levels of DNA
methylation were higher in the carcinoma scrapings
compared to the normal scrapings for 8 out of the 9 se-
lected genes (p < 0.001) (Fig. 2). The area under the
curve (AUC) for methylation ratio in cervical carcin-
oma revealed for 8 genes an AUC > 0.91 (Fig. 3). Be-
cause of an AUC of 0.59, PAX2 was excluded from
further analysis.
Diagnostic evaluation by QMSP for normal/LSIL versus
HSIL scrapings
In cohort 2, scrapings of 215 consecutive patients re-
ferred from population-based screening with an abnor-
mal Pap smear were used. The 8 genes that showed
differential methylation in the normal versus the cancer
scrapings were subsequently tested in this cohort.
Methylation levels and frequencies for all 8 genes ana-
lyzed (ZSCAN1, ST6GALNAC5, ANKRD18CP, CDH6,
GFRA1, GATA4, KCNIP4, and LHX8) increased with the
severity of the underlying histological lesion (p < 0.001)
(Fig. 4 and Table 3).
Considering all detected methylation as positive to
achieve higher sensitivity and/or specificity, genes
ZSCAN1, ST6GALNAC5, and KCNIP4 reached high
sensitivity (≥90 %) for detection of CIN2+ lesions, while
for CDH6, GATA4 and LHX8 sensitivity for CIN2+ was
between 73 and 84 % (Table 4). For ANKRD18CP and
Table 1 Verification, validation, and diagnostic evaluation of the highest ranking top 15 genes
Rank Gene Optimized Verification Validation 1st diagnostic evaluation 2nd diagnostic evaluation
1 ZSCAN1 Yes Yes Yes Yes Yes
2 PCDH17 Yes Noa
3 ST6GALNAC5 Yes Yes Yes Yes Yes
4 CLIC6 Yes No
5 RP11-89 K21.1.1 Yes No
6 ANKRD18CP Yes Yes Yes Yes Yes
7 PAX2b Yes Yes Yes No
8 CDH6 Yes Yes Yes Yes Yes
9 GFRA1 Yes Yes Yes Yes Yes
10 IRX1 Yes No
11 POU4F3 Yes Yes Noa
12 GATA4 Yes Yes Yes Yes Yes
13 MKX No
14 PAX2b Yes No
15 KCNIP4 Yes Yes Yes Yes Yes
16 LHX8 Yes Yes Yes Yes Yes
aExcluded due to high methylation in leukocytes
bSame gene, different region
Table 2 Methylation positivity in an external cohort of FFPE
samples to validate results of high methylation in CIN2+ lesions
and no methylation in normal cervices of the newly found
methylation markers
Gene Normal CIN2 CIN3 adCIS Carcinoma
ZSCAN1 4/16 8/8 7/8 3/3 12/13
ST6GALNAC5 0/16 1/6 4/8 2/3 9/12
ANKRD18CP 0/16 1/8 1/7 2/3 6/12
PAX2 1/14 6/8 7/8 3/3 5/13
CDH6 1/15 3/8 4/8 3/3 7/13
GFRA1 0/12 2/8 3/8 2/3 10/12
POU4F3a 2/14 6/7 3/7 3/3 11/12
GATA4 0/17 3/8 2/7 3/3 10/13
KCNIP4 0/17 6/8 5/8 3/3 10/12
LHX8 1/16 3/8 4/8 3/3 7/13
aExcluded due to high methylation in leukocytes
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Fig. 2 Methylation ratio of nine genes analyzed by QMSP in scrapings from normal (Nl) and cancer (Ca) patients. Methylation levels are significantly
higher in the cancer scrapings (all genes, except PAX2, p < 0.001)
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Fig. 3 ROC analysis of methylation ratio per gene
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Fig. 4 Methylation ratio of the eight genes analyzed by QMSP in scrapings from patients referred with an abnormal smear having a normal
cervix (No CIN), CIN1, CIN2, CIN3, or (mi)Ca. Methylation levels increase significantly with the severity of the underlying lesion (all p < 0.001)
Boers et al. Clinical Epigenetics  (2016) 8:29 Page 6 of 16
Table 3 Cytology according to the Papanicolaou system (Bethesda system) per histological subgroup. Methylation and HPV positivity of
the 8 new methylation markers and 4 known markers tested with QMSP in cervical scrapings from patients with CIN0, CIN1, CIN2, CIN3,
and (mi)Ca (n = 215)
Cytology CIN0 CIN 1 CIN2 CIN3 miCa
Pap2 (ASCUS) 9/27 (33 %) 9/38 (24 %) 2/45 (4 %) 0 0
Pap3A (LSIL) 18/27 (66 %) 27/38 (71 %) 36/45 (80 %) 18/61 (30 %) 5/44 (11 %)
Pap3B (HSIL) 0 2/38 (5 %) 6/45 (13 %) 33/61 (54 %) 27/44 (61 %)
Pap4 (HSIL) 0 0 1/45 (2 %) 10/61 (16 %) 8/44 (18 %)
Pap5 (miCa) 0 0 0 0 3/44 (7 %)
Unknown 0 0 0 0 1/44 (2 %)
New genes
ZSCAN1 20/27 (74 %) 28/38 (74 %) 41/45 (91 %) 55/61 (90 %) 44/44 (100 %)
ST6GALNAC5 22/27 (82 %) 33/38 (87 %) 39/45 (84 %) 56/61 (92 %) 41/44 (93 %)
ANKRD18CP 3/26 (12 %) 8/36 (22 %) 20/45 (44 %) 33/59 (56 %) 37/43 (86 %)
CDH6 10/26 (39 %) 15/36 (42 %) 25/45 (56 %) 40/59 (68 %) 42/43 (98 %)
GFRA1 1/26 (4 %) 4/36 (11 %) 9/45 (20 %) 23/59 (39 %) 35/43 (81 %)
GATA4 14/26 (54 %) 21/36 (58 %) 35/45 (78 %) 47/59 (80 %) 41/43 (95 %)
KCNIP4 24/27 (89 %) 36/38 (95 %) 44/45 (98 %) 61/61 (100 %) 43/44 (98 %)
LHX8 12/26 (46 %) 20/36 (56 %) 29/45 (64 %) 48/59 (81 %) 41/43 (95 %)
Known genes
C13ORF18 2/27 (7 %) 1/38 (3 %) 9/45 (20 %) 24/61 (39 %) 27/44 (61 %)
JAM3 3/27 (11 %) 3/38 (8 %) 18/45 (40 %) 39/61 (64 %) 37/44 (84 %)
EPB41L3 2/27 (7 %) 12/38 (32 %) 18/45 (40 %) 44/61 (72 %) 41/44 (93 %)
TERT 13/27 (48 %) 22/38 (58 %) 29/45 (64 %) 51/61 (84 %) 43/44 (98 %)
HPV test
hrHPV 12/26 (46 %) 24/36 (67 %) 36/45 (80 %) 49/59 (83 %) 31/43 (72 %)
Table 4 Sensitivity and specificity results for CIN2+ and CIN3+ in cervical scrapings from patients referred from population-based
screening with an abnormal Pap smear (n = 215)
Gene Sensitivity CIN2+ Specificity CIN2+ Sensitivity CIN3+ Specificity CIN3+
New genes
ZSCAN1 93 % 26 % 94 % 19 %
ST6GALNAC5 90 % 15 % 92 % 16 %
ANKRD18CP 61 % 82 % 69 % 71 %
CDH6 73 % 60 % 80 % 53 %
GFRA1 46 % 92 % 57 % 87 %
GATA4 84 % 44 % 87 % 35 %
KCNIP4 99 % 8 % 99 % 6 %
LHX8 80 % 40 % 87 % 43 %
Known genes
C13ORF18 40 % 95 % 49 % 89 %
EPB41L3 69 % 79 % 81 % 71 %
JAM3 63 % 91 % 72 % 78 %
TERT 82 % 46 % 90 % 42 %
HPV test
hrHPV 79 % 42 % 78 % 33 %
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GFRA1, sensitivity for CIN2+ was between 46 and 61 %,
and these genes showed especially high specificity (82–
92 %). In our analysis, we also included the 4 genes from
our previously reported 4-gene panel (C13ORF18, JAM3,
EPB41L3, and TERT) to compare sensitivity and specifi-
city of these known genes with the newly identified
methylation markers. The gene C13ORF18 showed re-
producible results as described previously [21] with high
specificity (95 %) and relatively low sensitivity for CIN2+
of 40 %. JAM3 and EPB41L3 showed sensitivities for
CIN2+ between 63 and 69 % and specificities between
79 and 91 %. The gene TERT was previously described
with high specificity, but this result could not be repro-
duced since specificity was only 46 % in our present ana-
lysis, while sensitivity for CIN2+ lesions was 82 %.
hrHPV status and triage testing
HrHPV testing was performed on the patient group
referred with abnormal cytology at population-based
screening. In 152/209 (73 %) samples, hrHPV could be
detected; as for 6 out of 215 patients, insufficient mater-
ial was available to perform HPV testing. Table 3 shows
hrHPV status in relation to underlying histological diag-
nosis. HrHPV was present in 12/26 (46 %) patients with-
out CIN lesion, 24/36 (67 %) CIN1 patients, 36/45
(80 %) CIN2 patients, 49/59 (83 %) CIN3 patients, and
31/43 (72 %) patients with micro-invasive cancer (miCa).
The sensitivity of hrHPV testing for CIN2+ was 79 %
with a specificity of 42 %. When comparing the sensitiv-
ity and specificity of hrHPV testing versus methylation
marker testing, the genes CDH6, GATA4, and LHX8
showed comparable sensitivity and specificity results to
hrHPV testing with sensitivity for CIN2+ between 73
and 84 % and specificity between 40 and 60 % (Table 4).
Table 5 shows sensitivity and specificity for CIN2+ and
CIN3+ in scrapings of hrHPV-positive women (n = 152),
which were comparable to the results for the whole
group, as shown in Table 4. The genes ZSCAN1,
ST6GALNAC5, and KCNIP4 again showed high sensitiv-
ity (≥92 %) for the detection of CIN2+, while for CDH6,
GATA4, EPB41L3, TERT, and ZSCAN16, sensitivity for
CIN2+ was between 72 and 85 %. For ANKRD18CP,
JAM3, C13ORF18, and GFRA1, sensitivity for CIN2+
was between 43 and 68 %; however, these genes showed
high specificity between 86 and 94 %. In the current
Dutch population-based screening program, women
with pap2/pap3a (ASCUS/LSIL) scrapings are retested
after 6 months with triage testing by hrHPV. Therefore,
we also show the results of triage testing by hrHPV and
methylation markers in this group (Table 5). Triage test-
ing by hrHPV shows a sensitivity for CIN2+ of 82 % with
a specificity of 41 %; GATA4, LHX8, and TERT show
comparable results.
Different combinations of genes were analyzed to find
the methylation marker panel with the highest combined
sensitivity and specificity. A sample was considered posi-
tive if one of the genes in the combination tested was
positive. By adding more than 3 genes in a combination,
specificity of the methylation test decreased, with min-
imal increase in sensitivity. The combinations of genes
with the highest combined sensitivity and specificity
for CIN2+ were JAM3/ANKRD18CP, C13ORF18/JAM3/
ANKRD18CP, and JAM3/GFRA1/ANKRD18CP with
sensitivities of 72, 74, and 73 %, respectively, which are
comparable to hrHPV testing (79 %). Specificity of the
combinations were 79, 76, and 77 %, respectively,
which are significantly higher than for hrHPV testing
(42 %) (p ≤ 0.05). Table 6 shows that for all other com-
binations, sensitivities for detecting CIN2+ lesions are
between 64 and 80 %, with a combined specificity be-
tween 58 and 88 %. For the detection of CIN3+ only,
overall the sensitivity slightly increased (72–85 %),
whereas the specificity decreased (48 and 72 %)
(Table 6).
In hrHPV-positive scrapings, the sensitivities and spec-
ificities for CIN2+ of the 3 best-performing combina-
tions (JAM3/ANKRD18CP, C13ORF18/JAM3/ANKRD
18CP, and JAM3/GFRA1/ANKRD18CP) were compar-
able (sensitivity 76–77 %; specificity 81–83 %) (Table 7)
to the population referred with an abnormal Pap smear.
The sensitivity to detect CIN3+ of these 3 combinations
again slightly increased to 85 %, while the specificity de-
creased 61–64 % (Table 7).
Discussion
In this study, we report new CIN2/3-specific methyla-
tion markers identified by a genome-wide DNA methyla-
tion screening strategy comparing CIN2/3 and normal
cervical cells. Diagnostic evaluation in cervical scrapings
shows that for 8 newly identified genes, the relative level
of methylation increases with the severity of the under-
lying histological lesion. Combining our newly identified
genes with our previously reported panel (C13ORF18,
JAM3, EPB41L3, and TERT) [21, 22] reveals that for the
combinations JAM3/ANKRD18CP, C13ORF18/JAM3/
ANKRD18CP, and JAM3/GFRA1/ANKRD18CP, sensitiv-
ities for CIN2+ were between 72 and 74 %, which was
comparable to the sensitivity for CIN2+ of hrHPV test-
ing (79 %). Specificities of these new gene panels were
between 76 and 79 %, which was significantly higher
(p ≤ 0.05) than the specificity for hrHPV testing (42 %)
in a triage setting after a positive Pap smear test result
in population-based screening. Furthermore, in hrHPV-
positive scrapings, sensitivity and specificity for CIN2+
of these best-performing combinations were comparable
to the population referred with an abnormal Pap smear.
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Due to introduction of primary prevention of cervical
cancer through prophylactic vaccination against hrHPV
types 16 and 18, involved in 70 % of cervical cancers,
the incidence of cervical neoplasia will decrease [14].
Current implementation of HPV vaccination programs
in Europe will not have a real impact on the incidence of
CIN2/3+ within the next 10–15 years. However, this de-
cline in incidence will most probably impair the diagnos-
tic performance of HPV testing and cytology triage
testing even more, resulting in less efficient population-
based screening programs [14]. There is therefore an ur-
gent need to further improve current methodology for
cervical cancer screening including new markers that are
not associated with HPV.
Our strategy revealed 164 genes, of which the highest
ranking 15 genes were validated in different steps. From
the 164 identified genes, 10 were described previously in
literature (POU4F3, WT1, TBX3, SOX1, COL6A2, ALK,
SOX17, PCDH10, CTNND2, APOBEC2) as being more
frequently methylated in CIN2/3 lesions and/or cervical
cancer compared to normal cervices, indicating the val-
idity of our approach. Of these 10 genes, POU4F3 was
further selected for validation in our approach, although
we could not confirm the data already reported [52].
This might be due to another primer design as we used
the DMR identified by MethylCap-seq. More CIN2+-spe-
cific markers are necessary since literature shows that
methylation markers were often tested on CIN3 scrap-
ings only and did not analyze scrapings of CIN2 pa-
tients [19, 20, 30].
In the current Dutch population-based screening pro-
gram, women with pap2/pap3a (ASCUS/LSIL) scrapings
are retested, after 6 months with triage testing by
hrHPV. We showed that some single methylation
markers had similar sensitivity and specificity for CIN2+
as hrHPV testing. However, combining methylation
Table 5 Sensitivity and specificity results for CIN2+ and CIN3+ in scrapings of hrHPV-positive women (n = 152). And in scraping of
pap2/pap3a (ASCUS/LSIL) patients (n = 124)
Sensitivity CIN2+ Specificity CIN2+ Sensitivity CIN3+ Specificity CIN3+
Only hrHPV-positive patients (n = 152)
ZSCAN1 94 % 36 % 96 % 23 %
ST6GALNAC5 92 % 19 % 94 % 15 %
ANKRD18CP 65 % 86 % 74 % 71 %
CDH6 72 % 64 % 83 % 57 %
GFRA1 51 % 92 % 64 % 85 %
GATA4 85 % 47 % 88 % 33 %
KCNIP4 98 % 11 % 99 % 7 %
LHX8 81 % 53 % 91 % 47 %
C13ORF18 43 % 94 % 54 % 88 %
EPB41L3 72 % 78 % 85 % 68 %
JAM3 68 % 94 % 80 % 76 %
TERT 81 % 47 % 90 % 43 %
Only pap2/3a patients (n = 124)
ZSCAN1 90 % 27 % 87 % 20 %
ST6GALNAC5 90 % 16 % 96 % 15 %
ANKRD18CP 38 % 82 % 41 % 75 %
CDH6 58 % 59 % 73 % 56 %
GFRA1 22 % 92 % 32 % 90 %
GATA4 78 % 44 % 77 % 35 %
KCNIP4 98 % 8 % 100 % 6 %
LHX8 70 % 49 % 86 % 46 %
C13ORF18 23 % 95 % 30 % 90 %
EPB41L3 51 % 78 % 74 % 72 %
JAM3 44 % 91 % 57 % 80 %
TERT 74 % 48 % 87 % 43 %
hrHPV 82 % 41 % 82 % 32 %
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markers might improve the sensitivity but mostly result-
ing in a decrease of specificity.
Cervical cancer screening will change to primary
hrHPV screening in the Netherlands in 2016. Because of
the relatively low specificity of the hrHPV test, a triage
test is necessary for hrHPV-positive women to prevent
unnecessary referral to the gynecologist. Although triage
testing with cytology is now mostly advocated, this test
has some disadvantages because of its subjectivity and
unreliability to test on material collected with self-
sampling [31]. Therefore, we analyzed the performance
of our methylation markers also in hrHPV-positive
scrapings. The combination JAM3/ANKRD18CP, C13OR
F18/JAM3/ANKRD18CP, and JAM3/GFRA1/ANKRD18
CP showed in the hrHPV-positive scrapings sensitivities
for CIN2+ between 76 and 77 % and specificities be-
tween 81 and 83 %. These results are better than for
other reported triage strategies in literature, such as im-
munohistochemical staining with p16INK4a and/or KI67
that report sensitivities for detecting CIN2/3 77–87 %
with a specificity of ~60 % [32–34] or for HPV 16/18
genotyping which reports sensitivity for CIN2/3 around
65 % with a specificity of 73 % [35]. Since our methyla-
tion panel was tested in a selected patient group that
was referred from population-based screening with ab-
normal cytology, further validation in hrHPV-positive
scrapings collected from a large cohort of women from
population-based screening should be performed. These
kinds of scrapings from real-life cohorts will become
available in the Netherlands after 2016 when primary
screening has changed to hrHPV testing.
The advantage of methylation marker analysis is that it
is an objective test and can be performed on the same
material used for hrHPV testing, which makes it also in-
teresting for self-sampled material [36–38]. Different
methylation markers already have been tested as a triage
test in hrHPV-positive women [19, 21, 30, 39–42]. How-
ever, for most of these markers, a cut-off value was set
above a certain methylation level in order to obtain high
specificity. The advantage of our methylation panel is
that no cut-off value is needed. If the PCR product is
negative (i.e., no amplification of specific product), the
Table 6 Combinations of different methylation markers to create a panel of genes most suited as test in scrapings ranked on
highest sensitivity (n = 215)
Gene combination Sensitivity CIN2+ Specificity CIN2+ Sensitivity CIN3+ Specificity CIN3+
JAM3/CDH6 80 % 58 % 85 % 48 %
ANKRD18CP/CDH6/EPB41L3 80 % 55 % 87 % 48 %
CDH6/EPB41L3 78 % 57 % 85 % 50 %
GFRA1/EPB41L3/CDH6 78 % 57 % 85 % 50 %
ANKRD18CP/CDH6 77 % 57 % 83 % 49 %
GFRA1/ANKRD18CP/CDH6 77 % 57 % 83 % 49 %
JAM3/EPB41L3/ANKRD18CP 76 % 71 % 84 % 60 %
C13ORF18/JAM3/ANKRD18CPa 74 % 76 % 80 % 62 %
ANKRD18CP/EPB41L3 74 % 74 % 83 % 64 %
GFRA1/EPB41L3/ANKRD18CP 74 % 74 % 84 % 64 %
C13ORF18/CDH6 74 % 58 % 80 % 51 %
JAM3/GFRA1/ANKRD18CPa 73 % 77 % 80 % 64 %
C13ORF18/JAM3/EPB41L3 73 % 72 % 83 % 64 %
GFRA1/CDH6 73 % 60 % 80 % 53 %
JAM3/ANKRD18CPa 72 % 79 % 79 % 65 %
JAM3/EPB41L3 72 % 75 % 83 % 66 %
JAM3/EPB41L3/GFRA1 72 % 76 % 83 % 66 %
GFRA1/EPB41L3 69 % 79 % 82 % 71 %
C13ORF18/EPB41L3 69 % 75 % 81 % 68 %
C13ORF18/JAM3/GFRA1 66 % 82 % 77 % 72 %
JAM3/GFRA1 65 % 86 % 76 % 75 %
C13ORF18/ANKRD18CP 65 % 79 % 72 % 67 %
C13ORF18/JAM3 64 % 88 % 73 % 76 %
GFRA1/ANKRD18CP 64 % 81 % 72 % 69 %
aThese gene combinations showed the highest combined sensitivity and specificity
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samples are called negative and any ratio above zero is
called positive. This unique feature of the selected genes
allows an objective and easy to interpret test. However,
although we focused on the methylation markers for
which no cut-off was required, the other identified
markers are still of interest for further investigation.
The gene ANKRD18CP (ankyrin repeat domain 18C,
pseudogene) is located on chromosome 9 and its func-
tion is still unknown. Moreover, methylation of
ANKRD18CP was not described before in any type of
cancer. The gene CDH6 (Cadherin 6) belongs to the
family of cadherins. Cadherins are membrane glycopro-
teins that mediate homophilic cell–cell adhesion and
play critical roles in cell differentiation and morphogen-
esis. Decreased expression of this gene may be associ-
ated with tumor growth and metastasis. It has recently
been described as a new transforming growth factor-β
(TGF-β) target in thyroid tumor patients [43]. The gene
GFRA1 (GDNF family receptor alpha 1) plays a key role
in the control of neuron survival and differentiation. It
has been described as differentially methylated between
cancerous and non-cancerous tissue obtained from lung
cancer patients based on DNA methylation profiles [44].
The strengths of our current study are (1) the
genome-wide approach with MethylCap-seq for specific
identification of differential methylation regions between
normal cervices and CIN2/3 lesions, (2) the systematic
verification and validation of the markers found using
carefully revealed cohorts, and (3) the selection of the
best-performing markers for diagnostic evaluation in
cervical scrapings. The limitation of the current study
was that the diagnostic evaluation of the markers could
not be performed on women with HPV-positive scrap-
ings with normal cytology, because referral for colpos-
copy with biopsies of this specific group is presently not
allowed by law in the Netherlands. Importantly, it has
been shown that approximately 25 % of the CIN2+ cases
are hrHPV positive with a subsequent normal cytology
[10, 42]. To study the effect of our results reported in
this manuscript is subject of future investigations.
Population-based screening is in transition and methy-
lation markers might be an important component in
Table 7 Combinations of different methylation markers to create a panel of genes most suited as triage test in HPV-positive scrap-
ings ranked on highest sensitivity (n = 152)
Gene combination Sensitivity CIN2+ Specificity CIN2+ Sensitivity CIN3+ Specificity CIN3+
JAM3/CDH6 80 % 64 % 88 % 50 %
ANKRD18CP/CDH6/EPB41L3 79 % 61 % 89 % 51 %
CDH6/EPB41L3 77 % 61 % 88 % 53 %
GFRA1/EPB41L3/CDH6 78 % 61 % 88 % 53 %
ANKRD18CP/CDH6 77 % 61 % 85 % 51 %
GFRA1/ANKRD18CP/CDH6 77 % 61 % 85 % 51 %
JAM3/EPB41L3/ANKRD18CP 78 % 72 % 88 % 58 %
C13ORF18/JAM3/ANKRD18CPa 77 % 81 % 85 % 61 %
ANKRD18CP/EPB41L3 75 % 75 % 86 % 63 %
GFRA1/EPB41L3/ANKRD18CP 75 % 75 % 86 % 63 %
C13ORF18/CDH6 73 % 61 % 83 % 54 %
JAM3/GFRA1/ANKRD18CPa 76 % 81 % 85 % 63 %
C13ORF18/JAM3/EPB41L3 76 % 72 % 86 % 60 %
GFRA1/CDH6 72 % 64 % 83 % 57 %
JAM3/ANKRD18CPa 76 % 83 % 85 % 64 %
JAM3/EPB41L3 75 % 75 % 86 % 63 %
JAM3/EPB41L3/GFRA1 75 % 75 % 86 % 63 %
GFRA1/EPB41L3 72 % 78 % 85 % 68 %
C13ORF18/EPB41L3 72 % 75 % 85 % 65 %
C13ORF18/JAM3/GFRA1 70 % 86 % 81 % 71 %
JAM3/GFRA1 69 % 89 % 81 % 74 %
C13ORF18/ANKRD18CP 68 % 83 % 76 % 67 %
C13ORF18/JAM3 69 % 92 % 80 % 74 %
GFRA1/ANKRD18CP 67 % 83 % 76 % 68 %
aThese gene combinations showed the highest combined sensitivity and specificity
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future screening settings. It is important to validate the
most interesting markers described in literature in a
population-based screening trial. Verification of the re-
sults by different groups is important to assure the
reproducibility of the methylation analysis. The combin-
ation of genes with the highest possible sensitivity and
specificity should be evaluated.
Conclusions
In conclusion, we identified several new CIN2/3-specific
methylation markers for detection of cervical neoplasia
in cervical scrapings. These newly found markers might
be applied as a triage test in hrHPV-positive women
from population-based screening.
Methods
General strategy
To characterize the DNA methylome of CIN2/3 lesions
and to identify new CIN2 or higher (CIN2+) methylation
markers, we applied the following strategy (see Fig. 1):
First, methylated DNA was enriched using MBD proteins
with subsequent paired-end sequencing (MethylCap-seq)
on DNA isolated from fresh-frozen macro-dissected epi-
thelial tissue of 18 CIN2/3 lesions (6 CIN2 and 12 CIN3),
20 normal cervices, and two pools of leukocyte DNA of
healthy volunteers. In order to identify differential methyl-
ated regions (DMRs), we retrieved the reads of promoter
and exon regions. We selected methylation markers that
showed clear-cut differences between the normal and
CIN2/3 cervices, while also the leukocyte count had to be
low, to prevent false-positive results. Markers were ranked
on high specificity (no methylation in the normal cervices)
and high sensitivity (methylation in CIN2/3 lesions). For
the highest ranking top 15 genes, MSP primers were de-
signed and methylation patterns were verified on the same
DNA, which originally was used for MethylCap-seq. This
first validation step enabled verification of MethylCap-seq
data by correlating MSP band intensity with the number
of reads from the MethylCap-seq. In the second validation
step, high prevalence of methylation in the CIN2/3 lesions
and no methylation in the normal cervices were analyzed
by MSP analysis on DNA isolated from a completely inde-
pendent cohort of patients (cervical cancer (n = 13),
CIN2/3 lesions (n = 19), and normal cervices (n = 17)).
DNA was isolated from macro-dissected formalin-fixed
paraffin-embedded (FFPE) epithelial tissue.
Finally, diagnostic evaluation of the newly discovered
methylation markers was performed by QMSP on cer-
vical scrapings. First, we tested the methylation ratios of
new biomarkers on a large series of randomly selected
scrapings from cervical cancer patients (n = 100) and a
similar age group of healthy controls (n = 89). Secondly,
the potential of the new methylation markers as a diag-
nostic tool was evaluated in a large series of scrapings
(n = 215) of randomly selected patients, referred with an
abnormal Pap smear at population-based screening.
Histology was used as the reference standard.
Patient samples
All patients referred to the outpatient clinic of the Uni-
versity Medical Center Groningen (UMCG) with cervical
cancer or an abnormal Pap smear at population-based
screening are routinely asked to participate in our on-
going “methylation study” which has been approved by
the institutional review board (IRB) of the UMCG. Cer-
vical tissue, scrapings, and clinicopathologic data are
prospectively collected and stored in our tissue bank.
Within our methylation study tissue samples, scrapings
and clinicopathologic data from normal cervices are also
collected from patients who planned to undergo a hys-
terectomy for non-malignant reasons. All cervical tissue
that was used for the normal control group was judged
as histopathologically normal. Patients referred with cer-
vical cancer are staged according to the FIGO criteria
with pelvic examination and biopsies under general
anesthesia. Cervical scrapings from both groups (cervical
cancer staging and benign gynecologic surgery) were
collected before surgery under general anesthesia. All
patients referred with an abnormal Pap smear at
population-based screening underwent an additional Pap
smear prior to colposcopy specifically for this study. In
this last cohort, women were only eligible when referred
with an abnormal smear at population-based screening
and not when they were referred to our hospital with
complaints. At colposcopy, biopsies and/or large loop
excision of the transformation zone (LLETZ) were per-
formed. The tissue samples were scored by an experi-
enced gynecologic pathologist, and the histological
classification was used as the reference standard. If no
interference with routine diagnostic evaluation was an-
ticipated, specimens from the CIN lesions were re-
trieved and stored at −80 °C. Clinicopathologic data
were retrieved from patient files and stored in our large
anonymous password-protected institutional gyneco-
logic oncology database. All patients gave written in-
formed consent.
For the frozen tissue samples used in the MethylCap-
seq analysis, the median age of the CIN2/3 patients was
35 years (interquartile range (IQR) 30–39) and for the
patients with normal cervices 43 years (IQR 41–44). For
the independent cohort of patients with FFPE samples,
the median age of the CIN2/3 patients was 37 years
(IQR 34–41), for the patients with normal cervices
43 years (IQR 40–44), and for the cervical cancer pa-
tients 49 years (IQR 42–54). For the cervical scrapings,
the median age of cervical cancer patients was 50 years
(IQR 39–64) and for the patients with normal cervices
47 years (IQR 43–53). The stages of cervical cancer
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patients were 1 (1 %) FIGO stage IA1, 31 (31 %) FIGO
stage IB1, 18 (18 %) FIGO stage IB2, 21 (21 %) FIGO
stage IIA, 17 (17 %) FIGO stage IIB, 1 (1 %) FIGO stage
IIIA, 8 (8 %) FIGO stage IIIB, and 3 (3 %) FIGO stage
IV. Histological classifications of the cervical cancer pa-
tients were 70 (70 %) squamous cell carcinoma (SCC), 21
(21 %) adenocarcinoma (AD), 3 (3 %) adenosquamous car-
cinoma (ASC), and 6 (6 %) undifferentiated carcinoma.
The median age of the patients referred with an abnormal
Pap smear was 37 years (IQR 32–43). The histological
classifications of these patients were 27 without CIN, 38
CIN1, 45 CIN2, 61 CIN3, and 44 miCa (29 SCC, 12 AD, 3
ASC). The Pap smears were classified according to the
Papanicolaou system. Table 3 shows, per histological sub-
group, the Pap classification (and translation to Bethesda).
From all frozen tissue samples used for MethylCap-seq
and the FFPE samples, 10-μm tissue sections were cut
and macro-dissection was performed to enrich for epi-
thelial cells. Before and after cutting, a hematoxylin and
eosin slide was made to check the presence of epithelial
cells. Cervical scrapings were collected in 5-ml ice-cold
phosphate-buffered saline (PBS 6.4 mM NA2HPO4;
1.5 mM KH2PO4; 0.14 M NaCl; 2.7 mM KCl) and kept
on ice until further processing. Of these 5-ml cell sus-
pensions, 1 ml was used for cytomorphological assess-
ment. The remaining 4 ml was centrifuged and the cell
pellet was suspended in 1-ml TRAP wash buffer and di-
vided in 4 fractions. Two fractions were stored as dry pellet
at −80 °C for DNA isolation as described previously [21].
DNA isolation
Tissue slides from FFPE tissue were deparaffinized using
100 % xylene followed by 100 % ethanol [17]. Genomic
DNA from fresh-frozen macro-dissected samples and
cervical scrapings was isolated by standard overnight
1 % SDS and proteinase K treatment, salt-chloroform ex-
traction, and isopropanol precipitation as described previ-
ously [21]. DNA pellets were washed with 70 % ethanol
and dissolved in 150 μl TE−4 (10 mM Tris/HCL; 0.1 mM
EDTA, pH 8.0). Genomic DNA was amplified in a multi-
plex PCR according to the BIOMED-2 protocol, to check
the DNA’s structural integrity [45]. For the MethylCap-seq
samples, DNA quantity was measured using Quant-iT™
PicoGreen® dsDNA Assay Kit according to manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA). For cervical
scrapings, DNA concentrations and 260/280 ratios were
measured using the Nanodrop ND-1000 Spectrophotom-
eter (Thermo Scientific, Waltham, MA, USA). A 260/280
ratio of >1.8 was required for all samples.
CpG-methylated island DNA capturing followed by next-
generation sequencing (MethylCap-seq)
Methylated DNA fragments were captured with methyl-
binding domains using the MethylCap kit according to
manufacturer’s instructions (Diagenode, Liège, Belgium).
The kit consists of the methyl-binding domain (MBD) of
human MeCP2, as a C-terminal fusion with glutathione-
S-transferase containing an N-terminal His6-tag. Before
capturing, DNA samples (500 ng) were sheared to a size
range of 300–1000 bps using a Bioruptor™ UCD-200
(Diagenode, Liège, Belgium) and fragments of ~300 bp
were isolated. Leukocyte DNA of 4 healthy controls were
included in 2 sets of 2 samples. Captured DNA was
paired-end-sequenced on the Illumina Genome Analyzer
II platform according to protocol (Illumina, San Diego,
CA, USA). Results were mapped on the nucleotide se-
quence using Bowtie software [46], visualized using Bio-
Bix’ H2G2 browser (http://h2g2.ugent.be/biobix.html) and
processed using the human reference genome (NCBI
build 37). The paired-end fragments were unique and lo-
cated within 400 bp of each other [47].
MethylCap-sequencing analysis
For statistical analysis, reads of promoter (−2000 bp
to +500 bp of transcription start site) and exon re-
gions were retrieved. In order to identify differences
between normal cervices and CIN2/3 lesions, we di-
chotomized the read data into methylation positive or
negative. Samples were considered negative if a sam-
ple showed either 0 or 1 read. Samples were consid-
ered methylation positive if a sample showed ≥3
reads in order to be more confident that these re-
gions were truly methylated. Subsequently, regions
were ranked based on highest specificity and highest
sensitivity for CIN2/3. The candidate markers should
fulfill the following criteria: (1) low/negative reads in
the leukocytes to prevent false-positive results. The
region was excluded if both leukocyte samples
showed >1 read or if 1 leukocyte sample showed >2
reads. (2) Markers should be unmethylated (0 or 1
read) in at least 75 % (15/20) of the normal cervix
group. (3) Markers should be methylated (≥3 reads)
in at least 28 % (5/18) of the CIN2/3 lesion group.
Verification and validation of MethylCap-sequencing data
by methylation specific PCR (MSP)
MSP primers were designed for the highest ranking top
15 genes (16 DMRs). Sodium bisulfite treatment of iso-
lated genomic DNA (1 μg/sample) was performed accord-
ing to the recommendations of the EZ DNA methylation
kit (Zymo, BaseClear, Leiden, the Netherlands). MSP de-
sign and analysis was performed using sequences derived
from the H2G2 browser. Each reaction was performed in
30-μl total reaction volume, containing: 600 nM of each
MSP primer, 1.5 μl of bisulfite-treated DNA (approxi-
mately 15 ng), standard PCR components (Applied Bio-
systems), and 0.5 U AmpliTaq Gold DNA polymerase
(Applied Biosystems). Condition of the MSP was 10 min
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hot-start at 95 °C; 95 °C for 60 s, 60 °C for 60 s, and 72 °C
60 s for a total of 40 cycles, with a final elongation step of
7 min at 72 °C. Leukocyte DNA from healthy women was
used as negative control and in vitro methylated (by SssI
enzyme) leukocyte DNA was used as positive control for
each MSP.
Quantitative methylation-specific PCR (QMSP)
QMSP was performed as described previously by our
group with an internal (FAM-ZEN/IBFQ)-labeled
hybridization probe for quantitative analyses [21]. Pri-
mer and probe sequences are available upon request.
β–actin was used as a methylation independent in-
ternal reference gene. QMSP reactions were performed
in 10 μl final volume, containing: 300 nM of forward
and reverse primers, 250 nM of hybridization probe,
5 μl of 2* QuantiTect Probe PCR Master Mix (Qiagen,
Hilden, Germany) and 2.5 μl bisulfite modified DNA
(approximately 25 ng). Each sample was analyzed in
triplicate by ABI PRISM® 7900HT Sequence Detection
System (Applied Biosystems). Negative and positive
controls were the same as used for MSP. Standard
curve analysis was performed on each plate and by
each primer-probe set on serial dilutions of in vitro
methylated leukocyte DNA. A DNA sample was con-
sidered methylated if at least 2 out of the 3 wells were
methylation positive with a Ct value below 50 and
DNA input of at least 225 pg β-actin. The relative level
of methylation of the region of interest was determined
by the following calculation: the average quantity of
the methylated region of interest divided by the aver-
age quantity of the reference β-actin gene and multi-
plied by 10,000 [48]. In our analysis, we also included
4 genes previously described by our group (C13ORF18,
JAM3, EPB41L3, and TERT) to compare sensitivity and
specificity of these known genes with the newly identi-
fied methylation markers. QMSP for these markers
was performed as previously described [21].
HPV testing
HrHPV testing was performed using general primer-
mediated PCR (GP5+/6+) as reported previously [48].
For HPV typing as well as detection of the clinical rele-
vant HPV infections, GP5+/6+-positive cases were tested
by COBAS® 4800 HPV test. The COBAS HPV test indi-
vidually detects HPV types 16 and 18, while at the same
time identifying 12 additional hrHPV types [49]. The
COBAS HPV test is routinely used in our iso-15189-
certified laboratory of molecular pathology on scrapings
from the national population-based screening program.
For the COBAS® HPV testing in this study, the PCR-
only workflow was used, since no liquid-based scrapings
in Preservcyt® were available but only already isolated
DNA. This workflow was first validated with DNA
isolated from clinical samples that were tested previously
in the diagnostic routine and this showed comparable
results to the liquid-based samples.
Statistical analysis
Statistical analysis was performed using SPSS software
package (SPSS 20, Chicago, IL, USA).
Spearman’s rank correlation coefficient was used to
compare the MethylCap-seq reads with the MSP band
intensity. Categorical methylation data were analyzed
using the Pearson χ2 test. Receiver operating characteristic
(ROC) curves were generated and the area under the
ROC curve (AUC) was used as a measure of test perform-
ance. The Mann–Whitney U test and Kruskall–Wallis test
was used to determine differences in methylation ratio in
2 groups or more, respectively. The student t test was
used to compare positive methylation and age. To com-
pare sensitivity and specificity of the patient group re-
ferred with abnormal cytology by DNA methylation
markers versus hrHPV, the extended McNemar test, de-
scribed by Hawass, was executed [50]. p values lower than
0.05 were considered statistically significant.
Additional file
Additional file 1: Table S1. Identified DMR’s with sensitivity and
specificity ranked on the sum of both. (XLSX 21 kb)
Abbreviations
ANKRD18CP: ankyrin repeat domain 18C, pseudogene; AUC: area under the
ROC curve; CDH6: cadherin 6; CIN: cervical intraepithelial neoplasia; CIN2+: CIN2
and higher; DMR: differential methylated region; FFPE: formalin-fixed paraffin-
embedded; GFRA1: GDNF family receptor alpha 1; hrHPV: high-risk human
papillomavirus; HSIL: high-grade CIN; IQR: interquartile range; IRB: institutional
review board; LLETZ: large loop excision of the transformation zone;
MBD: methyl-binding domain; MeDIP: methyl-DNA immunoprecipitation;
MSP: methylation-specific PCR; PBS: phosphate-buffered saline;
QMP: quantitative MSP; ROC: receiver operating characteristic; UMCG: University
Medical Center Groningen.
Competing interests
WvC, AGJvdZ, ES, and GBAW hold patents related to the content of the
manuscript. ES is a member of the scientific advisory board of Roche,
Hologic, and QCMD and received travel reimbursements from Roche,
Abbott, Hologic Inc., and QCMD. WvC is an employee of MDxHealth, Inc.,
Irvine, CA, USA.
Authors’ contributions
AB, RW, and RWvL performed the QMSP experiments. HGK collected all the
cervical scrapings and clinical data. AB, GHdB, and GBAW performed the
statistical analyses. HH reviewed the histological slides of patients’ samples.
WvC, TdM, GBAW, and SD performed and analyzed the MethylCap-seq data.
AB, AGJvdZ, ES, and GBAW conceived and designed the experiments. AB,
AGJvdZ, ES, and GBAW wrote the paper. All authors read and approved the
final manuscript.
Acknowledgements
This project was financed by the Dutch Cancer Society (RUG-NKB2009-4577).
Author details
1Department of Gynecologic Oncology, internal postal code DA13, Cancer
Reserch Center Groningen, University of Groningen, University Medical
Boers et al. Clinical Epigenetics  (2016) 8:29 Page 14 of 16
Center Groningen, PO box 30.001, 9700 RB Groningen, The Netherlands.
2Department of Epidemiology, Cancer Reserch Center Groningen, University
of Groningen, University Medical Center Groningen, Groningen, The
Netherlands. 3Department of Pathology, Cancer Reserch Center Groningen,
University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands. 4Department of Mathematical Modeling, Statistics and
Bioinformatics, Ghent University, Ghent, Belgium.
Received: 19 November 2015 Accepted: 2 March 2016
References
1. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic
that screening has prevented in the UK. Lancet. 2004;364:249–56.
2. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer
mortality in the member states of the European Union. Eur J Cancer. 2009;
45:2640–8.
3. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of
the European and North American studies on HPV testing in primary
cervical cancer screening. Int J Cancer. 2006;119:1095–101.
4. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A,
et al. Human papillomavirus DNA versus Papanicolaou screening tests for
cervical cancer. N Engl J Med. 2007;357:1579–88.
5. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, et al.
Comparison of cervical cancer screening strategies incorporating different
combinations of cytology, HPV testing, and genotyping for HPV 16/18:
results from the ATHENA HPV study. Am J Obstet Gynecol. 2013;208:3.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et
al. Human papillomavirus is a necessary cause of invasive cervical cancer
worldwide. J Pathol. 1999;189:12–9.
7. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy
of HPV-based screening for prevention of invasive cervical cancer: follow-up
of four European randomised controlled trials. Lancet. 2014;383:524–32.
8. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A,
et al. Efficacy of human papillomavirus testing for the detection of invasive
cervical cancers and cervical intraepithelial neoplasia: a randomised
controlled trial. Lancet Oncol. 2010;11:249–57.
9. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S,
et al. Human papillomavirus DNA testing for the detection of cervical
intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a
randomised controlled implementation trial. Lancet. 2007;370:1764–72.
10. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW,
Heideman DA, et al. Human papillomavirus testing for the detection of
high-grade cervical intraepithelial neoplasia and cancer: final results of the
POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78–88.
11. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence
regarding human papillomavirus testing in secondary prevention of cervical
cancer. Vaccine. 2012;30 Suppl 5:F88–99.
12. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al.
Overview of human papillomavirus-based and other novel options for
cervical cancer screening in developed and developing countries. Vaccine.
2008;26 Suppl 10:K29–41.
13. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al.
Evaluation of human papillomavirus testing in primary screening for cervical
abnormalities: comparison of sensitivity, specificity, and frequency of referral.
JAMA. 2002;288:1749–57.
14. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact
of HPV vaccination on the accuracy of cervical cancer screening: the need
for a paradigm change. Arch Med Res. 2009;40:478–85.
15. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for
early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107–16.
16. Steenbergen RD, Snijders PJ, Heideman DA, Meijer CJ. Clinical implications
of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat
Rev Cancer. 2014;14:395–405.
17. Yang N, Nijhuis ER, Volders HH, Eijsink JJ, Lendvai A, Zhang B, et al. Gene
promoter methylation patterns throughout the process of cervical
carcinogenesis. Cell Oncol. 2010;32:131–43.
18. Bierkens M, Hesselink AT, Meijer CJ, Heideman DA, Wisman GB, van der Zee
AG, et al. CADM1 and MAL promoter methylation levels in hrHPV-positive
cervical scrapes increase proportional to degree and duration of underlying
cervical disease. Int J Cancer. 2013;133:1293–9.
19. Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM,
Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and
MAL: an objective triage tool for high-risk human papillomavirus DNA-
positive women. Clin Cancer Res. 2011;17:2459–65.
20. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, et al. Quantitative
DNA methylation analysis detects cervical intraepithelial neoplasms type 3
and worse. Cancer. 2010;116:4266–74.
21. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al.
A four-gene methylation marker panel as triage test in high-risk human
papillomavirus positive patients. Int J Cancer. 2012;130:1861–9.
22. Yang N, Eijsink JJ, Lendvai A, Volders HH, Klip H, Buikema HJ, et al.
Methylation markers for CCNA1 and C13ORF18 are strongly associated with
high-grade cervical intraepithelial neoplasia and cervical cancer in cervical
scrapings. Cancer Epidemiol Biomarkers Prev. 2009;18:3000–7.
23. Reesink-Peters N, Wisman GB, Jeronimo C, Tokumaru CY, Cohen Y, Dong
SM, et al. Detecting cervical cancer by quantitative promoter
hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer
Res. 2004;2:289–95.
24. Laird PW. Principles and challenges of genomewide DNA methylation
analysis. Nat Rev Genet. 2010;11:191–203.
25. Lendvai A, Johannes F, Grimm C, Eijsink JJ, Wardenaar R, Volders HH, et al.
Genome-wide methylation profiling identifies hypermethylated biomarkers
in high-grade cervical intraepithelial neoplasia. Epigenetics. 2012;7:1268–78.
26. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification
of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008;
123:161–7.
27. Chen YC, Huang RL, Huang YK, Liao YP, Su PH, Wang HC, et al. Methylomics
analysis identifies epigenetically silenced genes and implies an activation of
beta-catenin signaling in cervical cancer. Int J Cancer. 2014;135:117–27.
28. Serre D, Lee BH, Ting AH. MBD-isolated Genome Sequencing provides a
high-throughput and comprehensive survey of DNA methylation in the
human genome. Nucleic Acids Res. 2010;38:391–9.
29. Rauch TA, Pfeifer GP. DNA methylation profiling using the methylated-CpG
island recovery assay (MIRA). Methods. 2010;52:213–7.
30. Overmeer RM, Louwers JA, Meijer CJ, Van Kemenade FJ, Hesselink AT,
Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation
analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive
women. Int J Cancer. 2011;7:6.
31. Gok M, van Kemenade FJ, Heideman DA, Berkhof J, Rozendaal L, Spruyt JW,
et al. Experience with high-risk human papillomavirus testing on vaginal
brush-based self-samples of non-attendees of the cervical screening
program. Int J Cancer. 2012;130:1128–35.
32. Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, et al.
Screening for cervical cancer precursors with p16/Ki-67 dual-stained
cytology: results of the PALMS study. J Natl Cancer Inst. 2013;105:1550–7.
33. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco
L, et al. Use of p16-INK4A overexpression to increase the specificity of
human papillomavirus testing: a nested substudy of the NTCC randomised
controlled trial. Lancet Oncol. 2008;9:937–45.
34. Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, et al.
Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-
positive women according to baseline p16-INK4A results: a prospective
analysis of a nested substudy of the NTCC randomised controlled trial.
Lancet Oncol. 2013;14:168–76.
35. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal
L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in
population-based cervical screening. Int J Cancer. 2012;130:602–10.
36. Eijsink JJ, Yang N, Lendvai A, Klip HG, Volders HH, Buikema HJ, et al.
Detection of cervical neoplasia by DNA methylation analysis in cervico-
vaginal lavages, a feasibility study. Gynecol Oncol. 2011;120:280–3.
37. Verhoef VM, Dijkstra MG, Bosgraaf RP, Hesselink AT, Melchers WJ, Bekkers RL,
et al. A second generation cervico-vaginal lavage device shows similar
performance as its preceding version with respect to DNA yield and HPV
DNA results. BMC Womens Health. 2013;13:21.
38. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA,
Massuger LF, et al. DNA methylation analysis in self-sampled brush material
as a triage test in hrHPV-positive women. Br J Cancer. 2014;111:1095–101.
39. Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Cadman L, Austin J,
Szarewski A, et al. A DNA methylation classifier of cervical precancer
based on human papillomavirus and human genes. Int J Cancer. 2014;135:
1425–32.
Boers et al. Clinical Epigenetics  (2016) 8:29 Page 15 of 16
40. Vasiljevic N, Scibior-Bentkowska D, Brentnall AR, Cuzick J, Lorincz AT.
Credentialing of DNA methylation assays for human genes as diagnostic
biomarkers of cervical intraepithelial neoplasia in high-risk HPV positive
women. Gynecol Oncol. 2014;132:709–14.
41. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al.
A promising DNA methylation signature for the triage of high-risk human
papillomavirus DNA-positive women. PLoS One. 2014;9:3.
42. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA,
Hesselink AT, et al. Triage by methylation-marker testing versus cytology in
women who test HPV-positive on self-collected cervicovaginal specimens
(PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol.
2014;15:315–22.
43. Sancisi V, Gandolfi G, Ragazzi M, Nicoli D, Tamagnini I, Piana S, et al. Cadherin 6
is a new RUNX2 target in TGF-beta signalling pathway. PLoS One. 2013;8:9.
44. Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, et al.
Genome-scale analysis of DNA methylation in lung adenocarcinoma and
integration with mRNA expression. Genome Res. 2012;22:1197–211.
45. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M,
Lavender FL, et al. Design and standardization of PCR primers and protocols
for detection of clonal immunoglobulin and T-cell receptor gene
recombinations in suspect lymphoproliferations: report of the BIOMED-2
Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.
46. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient
alignment of short DNA sequences to the human genome. Genome Biol.
2009;10:3.
47. De Meyer T, Mampaey E, Vlemmix M, Denil S, Trooskens G, Renard JP, et al.
Quality evaluation of methyl binding domain based kits for enrichment
DNA-methylation sequencing. PLoS One. 2013;8:3.
48. Wisman GB, Nijhuis ER, Hoque MO, Reesink-Peters N, Koning AJ, Volders HH,
et al. Assessment of gene promoter hypermethylation for detection of
cervical neoplasia. Int J Cancer. 2006;119:1908–14.
49. Cui M, Chan N, Liu M, Thai K, Malaczynska J, Singh I, et al. Clinical performance
of Roche Cobas 4800 HPV Test. J Clin Microbiol. 2014;52:2210–1.
50. Hawass NE. Comparing the sensitivities and specificities of two diagnostic
procedures performed on the same group of patients. Br J Radiol. 1997;70:
360–6.
51. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J.
Liquid compared with conventional cervical cytology: a systematic review
and meta-analysis. Obstet Gynecol. 2008;111:167–77.
52. Pun PB, Liao YP, Su PH, Wang HC, Chen YC, Hsu YW, Huang RL, Chang CC,
Lai HC. Triage of high-risk human papillomavirus-positive women by
methylated POU4F3. Clin Epigenetics. 2015;7:85. 015-0122-0.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Boers et al. Clinical Epigenetics  (2016) 8:29 Page 16 of 16
